Beebe S J, Reimann E M, Schlender K K
J Biol Chem. 1984 Feb 10;259(3):1415-22.
We recently reported the partial purification of a cAMP-independent and Ca2+-calmodulin-independent glycogen synthase kinase from porcine renal cortex (Schlender, K. K., Beebe, S. J., and Reimann, E. M. (1981) Cold Spring Harbor Conf. Cell Proliferation, 389-400). Subsequent purification indicated that the enzyme preparation consisted of at least three forms of glycogen synthase kinase which could be resolved by ATP gradient elution from aminoethylphosphate-agarose (AEP-agarose). The predominant form of glycogen synthase kinase, which eluted from AEP-agarose between 2 and 6 mM ATP, was purified approximately 800-fold and is designated GSK-A1. It had a molecular weight of 45,000-50,000 as determined by gel filtration and sucrose density gradient centrifugation. It catalyzed the transfer of 1 mol of 32P/mol of synthase subunit into a low molecular weight (10,000) CNBr peptide which was tentatively identified as Ser-7 (site 2) by high performance liquid chromatography. This phosphorylation decreased the activity ratio (activity in the absence of glucose-6-P divided by activity in the presence of 7.2 mM glucose-6-P) from 0.95 to about 0.55. GSK-A1 appeared to be specific for and had low s0.5 values for both substrates, ATP (13 microM) and glycogen synthase (0.3-0.4 microM). The enzyme could not use GTP as the phosphate donor. GSK-A1 was not affected by the protein kinase inhibitor, cAMP, cGMP, Ca2+-calmodulin, EGTA, or trifluoperazine and had a broad pH optimum (pH 7.0-8.5). A second form, GSK-A2, was eluted from AEP-agarose between 7 and 9 mM ATP. GSK-A2 could transfer a 2nd mol of 32P/mol of synthase subunit and decreased the activity ratio to 0.30. The interrelation among these multiple forms is not clear, but the data suggest that multiple kinases are required to form the highly inactivated glycogen synthase in renal tissues.
我们最近报道了从猪肾皮质中部分纯化出一种不依赖环磷酸腺苷(cAMP)且不依赖钙离子-钙调蛋白的糖原合酶激酶(施伦德,K.K.,比贝,S.J.,以及赖曼,E.M.(1981年)《冷泉港细胞增殖会议》,第389 - 400页)。后续的纯化表明,该酶制剂至少由三种糖原合酶激酶形式组成,可通过从氨乙基磷酸琼脂糖(AEP - 琼脂糖)上进行ATP梯度洗脱来分离。从AEP - 琼脂糖上在2至6 mM ATP之间洗脱的糖原合酶激酶的主要形式,纯化了约800倍,被命名为GSK - A1。通过凝胶过滤和蔗糖密度梯度离心测定,其分子量为45,000 - 50,000。它催化将1摩尔的32P/摩尔的合酶亚基转移到一个低分子量(10,000)的溴化氰肽中,通过高效液相色谱初步鉴定为丝氨酸 - 7(位点2)。这种磷酸化使活性比(在无6 - 磷酸葡萄糖时的活性除以在有7.2 mM 6 - 磷酸葡萄糖时的活性)从0.95降至约0.55。GSK - A1似乎对两种底物ATP(13 microM)和糖原合酶(0.3 - 0.4 microM)都具有特异性且米氏常数(Km)值较低。该酶不能使用GTP作为磷酸供体。GSK - A1不受蛋白激酶抑制剂、cAMP、cGMP、钙离子 - 钙调蛋白、乙二醇双四乙酸(EGTA)或三氟拉嗪的影响,并且具有较宽的最适pH值(pH 7.0 - 8.5)。第二种形式,GSK - A2,从AEP - 琼脂糖上在7至9 mM ATP之间洗脱。GSK - A2可以将第二摩尔的32P/摩尔的合酶亚基转移,并将活性比降至0.30。这些多种形式之间的相互关系尚不清楚,但数据表明在肾组织中需要多种激酶来形成高度失活的糖原合酶。